Today's Top Stories


Hot Topics


Comment & Analysis »

GlobalData Healthcare

FDA raises warning flag over Viberzi safety in IBS-D

In March 2017, the FDA issued a warning against Allergan’s Viberzi (eluxadoline), which was approved in May 2015 in the US for the treatment of diarrhoea-predominant irritable bowel syndrome...

FDA raises warning flag over Viberzi safety in IBS-D
GlobalData Healthcare

Inclisiran: a novel approach to targeting cholesterol and patient needs

Inclisiran: a novel approach to targeting cholesterol and patient needs
GlobalData Healthcare

Roche’s Ocrevus expected to be a game-changer for the multiple sclerosis market

Roche’s Ocrevus expected to be a game-changer for the multiple sclerosis market
GBI Research

Trump’s new FDA Commissioner: A reasonable pick despite conflicts of interest

Trump’s new FDA Commissioner: A reasonable pick despite conflicts of interest
GlobalData Healthcare

Novo Nordisk’s long-acting growth hormone somapacitan likely to conquer the adult GHD market in Japan

Novo Nordisk’s long-acting growth hormone somapacitan likely to conquer the adult GHD market in Japan

Company Releases »

Changing Trial Logistics and How They Effect Development

Fisher Clinical Services
Changing Trial Logistics and How They Effect Development

Characterisation of Tableting Properties Measures with a Multi-Functional Compaction Instrument

Gamlen Instruments
Characterisation of Tableting Properties Measures with a Multi-Functional Compaction Instrument

Dry Powder Inhaler Monodose RS01

Plastiape Group Dry Powder Inhaler Monodose RS01

Contamination Control Floor Solutions

Dycem
Contamination Control Floor Solutions

Klocke uses NA and ML for Quality Storage

Munters Klocke uses NA and ML for Quality Storage

Pharmaceutical Insights »

Pharmaceutical Industry Reports »

India’s 2016 clinical trials activity back to 2008 levels

India’s 2016 clinical trials activity back to 2008 levels

Biogen will retain the lion’s share of the neurology market

Biogen will retain the lion’s share of the neurology market

Seven kings of diabetes will remain in power for years to come

Seven kings of diabetes will remain in power for years to come

Novartis: most clinical trials initiated in a year

Novartis: most clinical trials initiated in a year








cachename:HomePagecachekey:rd-1665407042_1729060782_rd-488908060_1460672566_ap1460672566_1729060782_-1100201212